Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Using the National TB Indicators Project to Select a Focus Area for Program Evaluation										Related Pages
										Return to Main Menu
**Steps to Help You Identify a Focus Area**
The following steps will guide you through the process of using NTIP to identify a TB program evaluation focus area for your evaluation plan. You do not have to complete all steps.book iconStep 1. Review your jurisdiction’s NTIP indicator summary report.Performance on the Known HIV Status indicator has decreased during the previous 2 years and is less than the national performance target.Example-NTIP-indicator-summaryPerformance on the Known HIV Status indicator has decreased during the previous 2 years and is less than the national performance target.
resize iconView Larger
ClosePerformance on the Known HIV Status indicator has decreased during the previous 2 years and is less than the national performance target.Example-NTIP-indicator-summary
Performance on the Known HIV Status indicator has decreased during the previous 2 years and is less than the national performance target.
download iconDownload Imageimage icon[JPG, NAN ]
The indicator summary report (see example NTIP indicator summary) provides information about your jurisdiction’s progress in meeting each National Performance Target.
Review the trends for your program indicators to determine if performance is improving, staying the same, or getting worse?
After reviewing the example indicator summary report, if you find that performance on the Known HIV Status indicator has decreased during the previous 2 years and is less than the National Performance Target, you may decide to take a closer look at the Known HIV (human immunodeficiency virus) Status indicator.Note: The examples provided here are based on the frozen 2019 dataset.  However, these steps can also be done using the current dataset or other available datasets in NTIP.chart bar iconStep 2. Review your jurisdiction’s NTIP indicator report.SMART Objective: Specific, Measurable, Achievable, Realistic, and Time-BoundExample-NTIP-indicator-reportCohort Period- (n) numbers (numerator and denominator) that are used to calculate the performance indicator (percentage of patients with known HIV status)
resize iconView Larger
CloseSMART Objective: Specific, Measurable, Achievable, Realistic, and Time-BoundExample-NTIP-indicator-report
Cohort Period- (n) numbers (numerator and denominator) that are used to calculate the performance indicator (percentage of patients with known HIV status)
download iconDownload Imageimage icon[JPG, NAN ]
NTIP indicator reports (see example NTIP indicator report ) include Specific, Measurable, Achievable, Realistic, and Time-bound (SMART) objectives that directly relate to the National TB Program Objectives and 2020 Performance Targets.
Using SMART objectives will help your evaluation plan succeed by giving you a sense of direction and helping you organize and reach your goals.
The table beneath the graph in each NTIP indicator report tells you the number of cases that were used in the numerator and denominator for calculating the percentage associated with each indicator. For example, in the HIV Status indicator report,
How many patients were HIV-positive (HIV+) and how many were HIV-negative (HIV-)?
You then review the numbers in the table. Do they seem correct? Are they what you expected?ballot check iconStep 3. Take a closer look at your data using the NTIP line list feature.Example NTIP Line ListExample-NTIP-linelist"D" column shows the HIV status for each patient which helps explain why the HIV objective was met or not.
"F"column shows which patients were in the eligible cohort for HIV status.
"G" column shows if the patient met the HIV objective.
resize iconView Larger
CloseExample NTIP Line ListExample-NTIP-linelist
"D" column shows the HIV status for each patient which helps explain why the HIV objective was met or not.
"F"column shows which patients were in the eligible cohort for HIV status.
"G" column shows if the patient met the HIV objective.
download iconDownload Imageimage icon[JPG, NAN ]
The NTIP line list (see example NTIP line list) tells you the cases and specific variables for each case that were used in the NTIP indicator report. With the NTIP line list you can
Review which patients were part of the indicator cohort for your specific indicator of interest. (In this example, “HIV cohort” means patients who were eligible to have an HIV test.)
Determine exactly why patients who were part of the eligible indicator cohort did not meet the objective.
After reviewing the partial example line list, you see that 21 patients were in the eligible cohort for HIV status. Here are some concerns that suggest areas needing improvement:
None of the 21 patients met the objective.
9 of those 21 (43%) patients were not offered an HIV test.
Two blank cells indicate that information was not entered at all.Note: Not all NTIP users have access to the NTIP line list feature. If you need access, please contact the NTIP coordinator in your jurisdiction or send an e-mail to DTBESupport@cdc.gov.map iconStep 4. Review the State and City TB Report.The state and city report (see example state and city TB report graph) shows selected indicator performance across 50 states and 9 cities.
How is your jurisdiction performing, compared with similarly sized jurisdictions?
Using the state and city TB report, you could identify other similarly sized jurisdictions and consider contacting them to discuss their approaches to improving indicator performance.Example State and City TB Report Graph Example State and City TB Report Graphresize iconView Larger
CloseExample State and City TB Report Graph Example State and City TB Report Graph
download iconDownload Imageimage icon[JPG, NAN ]user cog iconStep 5. Develop your program evaluation plan.In this example,
After reviewing the NTIP indicator summary data and NTIP report (Steps 1 and 2), you identified Known HIV Status as a potential evaluation focus area.
By looking more closely at the details of the data using the NTIP line list (Step 3), you found that your jurisdiction probably did not meet this objective because some patients were recorded as not offered an HIV test.
Who else should be made aware of these results? Get engagement and support from stakeholders.
Your plan should include how you will determine the barriers to offering HIV testing.
You should also review the patients’ medical record to make sure the HIV test results are the same as the HIV test results in the NTIP linelist. This is an opportunity to correct any data errors.
By reviewing the state and city TB report (Step 4), you learned that other jurisdictions with a similar case count as yours were able to meet the 2020 National Performance Target for the Known HIV Status indicator.
By focusing on this area for evaluation, your program evaluator can develop an evaluation plan for understanding why results for some patients indicate that they are not offered HIV tests, but others are. Findings from this evaluation can be used to develop a remediation or action plan for modifying protocols or developing interventions, or for other follow-up activities that can improve your program performance.Definitions for Key Terms used in this Tool**Indicator** – measures developed to assess progress toward the National TB Program Objectives
**Indicator Cohort** – the total number of patients who are eligible to meet the performance objective for an indicator
NTIP (National TB Indicators Project) – a web-based performance-monitoring tool that tracks your jurisdiction’s progress toward national TB program objectives
National TB Program Objective – the long-term expectation for TB program outcomes
**National TB Performance Target** – the quantitative goal for TB program outcomes
**SMART Objective (Specific, Measurable, Achievable, Relevant, Time-bound)** – statements that describe the results you want to achieve and how you will achieve themTop of Page
							
					
						Page last reviewed:  May 4, 2020					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue